| References: |
Selumetinib (AZD6244) is an orally bioavailable small molecule with potential antineoplastic activity. Selumetinib inhibits mitogen-activated protein kinase kinases (MEK or MAPK/ERK kinases) 1 and 2, which may prevent the activation of MEK1/2-dependent effector proteins and transcription factors, and so may inhibit cellular proliferation in MEK-overexpressing tumor cells. MEK 1 and 2 are dual-specificity kinases that are essential mediators in the activation of the RAS/RAF/MEK/ERK pathway, are often upregulated in various tumor cell types, and are drivers of diverse cellular activities, including cellular proliferation. Check For active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).
For the detailed information about the solubility of AZD6244 (Selumetinib, ARRY-142886) in water, the solubility of AZD6244 (Selumetinib, ARRY-142886) in DMSO, the solubility of AZD6244 (Selumetinib, ARRY-142886) in PBS buffer, the animal experiment（test） of AZD6244 (Selumetinib, ARRY-142886),the in vivo,in vitro and clinical trial test of AZD6244 (Selumetinib, ARRY-142886),the cell experiment（test） of AZD6244 (Selumetinib, ARRY-142886),the IC50, EC50 and Affinity of AZD6244 (Selumetinib, ARRY-142886), please contact DC Chemicals. |
